Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon Substitution Drug List

 
According to the Law No. 91 issued on 2010 related to the Pharmacist substitution right, the Ministry of Public Health conceived the Substitution Drug list. It is presented as a scientific, objective, reliable, accurate and accessible listing. This list is a helpful tool for Pharmacists and Health professionals and an information tool for patients as well.

The Substitution Drug List was compiled by a team of Pharmacists and Physicians from the Ministry of Public Health. It was inspired by the French Repertory of Generic Groups and the Lebanese National Drug Index (LNDI) which is the reference Guide for medicines in Lebanon.

The substitution could be done between an innovator product and a generic, based on the Ministry of Public Health Substitution list, providing that the product delivered is cheaper and has obtained the patient’s consent.

This Substitution Drug List, lists drugs, dosage forms, package sizes, drug strengths and other information registered at the Ministry of Public Health. It is divided into sections based on the Anatomical Therapeutic Chemical (ATC) classification system. The Innovator product is listed before the Generic products.

Information is shown in a convenient format with trade information in italics:
 
  ATCcode          
  Trade Name & Strength   B=Brand
G=Generic
 
  Route Form Container Presentation Code MOPH Registration Number at MOPH
    Active Ingredients with their respective dosage    
    Agent importing product Manufacturer Country of Origin  
        Responsible Party Country of Responsible Party
Each medication listing contains the following information:
  • ATC classification and code.
  • Trade name and strength of the formulation as registered at the Ministry of Public Health (MOH)
  • Generic (G) or Brand product (B)
  • Composition of the marketed form with the corresponding dosage of each active ingredient.
  • Form &presentation.
  • The local importer (agent), manufacturer and identified country of origin.
  • The Responsible Party and identified country.
  • The Ministry of Public Health database serial number (Code MOH) and legal registration document number (MOH reg)
 
The Substitution Drug List can be accessed from the official website of the Ministry of Public Health: www.moph.gov.lb

The Substitution Drug List welcomes comments from healthcare professionals. Please send comments to: mphealth@cyberia.net.lb
 
 
Lebanon Substitution Drug List - First Edition 2015 (Revised)
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BD02 BERIATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
J05AF10 HEPCAVIR 1 G Entecavir monohydrate - 1mg 1mg Tablet, film coated L.L
J05AF10 HEPCAVIR 0.5 G Entecavir monohydrate - 0.5mg 0.5mg Tablet, film coated L.L
B06AC05 TAKHZYRO BioTech Lanadelumab - 300mg/2ml 300mg Injectable solution L.L
N05AX13 TREVICTA B Paliperidone - 525mg 525mg Injectable suspension, prolonged release L.L
N05AX13 TREVICTA B Paliperidone - 350mg 350mg Injectable suspension, prolonged release L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 150mg 150mg Injectable suspension, prolonged release L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 100mg 100mg Injectable suspension, prolonged release L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg week 1, Venetoclax - 50mg week 2, Venetoclax - 100mg week 3&4 Tablet L.L
L04AC05 USTEKIREL BioTech Ustekinumab - 90mg 90mg Injectable solution L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 15mg 15mg Capsule L.L
L04AX04 LENALIDOMIDE NEAPOLIS G Lenalidomide - 10mg 10mg Capsule L.L
L01CE02 IRINOTECAN GP PHARM G Irinotecan HCl trihydrate - 100mg/5ml 100mg/5ml Injectable concentrated solution L.L
L01XA03 OXALIPLATIN EBEWE G Oxaliplatin - 50mg/10ml 50mg/10ml Injectable concentrated solution L.L
L01CA04 EBERELBIN G Vinorelbine (tartrate) - 50mg/5ml 50mg/5ml Injectable concentrated solution L.L
L01BC01 ALEXAN G Cytarabine - 1,000mg/20ml 1,000mg/20ml Injectable solution L.L
L01CD02 DOCETAXEL EBEWE G Docetaxel - 80mg/8ml 80mg/8ml Injectable solution L.L
L04AA06 MYFORTIC B Mycophenolic acid (sodium) - 360mg 360mg Tablet, gastroresistant L.L
N03AF01 TEGRETOL B Carbamazepine - 2% 2% Suspension L.L
L01DB01 DOXORUBICINE EBEWE G Doxorubicin HCl - 2mg/ml 50mg/25ml Injectable concentrated solution L.L
L01CE02 IRINOTECAN THYMOORGAN G Irinotecan HCl - 40mg/2ml 40mg/2ml Injectable concentrated solution L.L
L01AA06 HOLOXAN B Ifosfamide - 1g 1g Injectable powder for solution L.L
L01AX03 TEGOZOL G Temozolomide - 250mg 250mg Capsule L.L
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 100mg 100mg Injectable lyophilised powder for solution L.L
L04AA44 RINVOQ B Upadacitinib - 15mg 15mg Tablet, prolonged release L.L
L01CD02 DOCETAXEL ACCORD G Docetaxel - 20mg/ml 20mg/1ml Injectable concentrate for solution L.L
L01DC01 BLEOCIN B Bleomycin (sulfate) - 15U 15U Injectable lyophilised powder for solution L.L
J05AB14 VALGANCICLOVIR ARROW G Valganciclovir (HCl) - 450mg 450mg Tablet, coated L.L
M05BX04 PROLIA BioTech Denosumab - 60mg/ml 60mg/ml Injectable solution L.L
B02BX06 HEMLIBRA BioTech Emicizumab - 150mg/ml 150mg/ml Injectable solution L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026